Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
Clinical Neuropharmacology|February 1, 1992
Quantifying drug-induced changes in parkinsonian rigidity using an instrumental measure of activated stiffnessM P Caligiuri, D R GalaskoInternational Journal of Geriatric Psychiatry|September 26, 2001
Extrapyramidal signs and cognitive abilities in Alzheimer's diseaseM P Caligiuri, G Peavy, D R GalaskoStatistics in Medicine|June 9, 2000
Measuring cognitive change in a cohort of patients with Alzheimer's diseaseD R Galasko, R L Gould, I S Abramson, et al.Neurology|October 15, 2003
Neuromotor abnormalities and risk for psychosis in Alzheimer's diseaseM P Caligiuri, G Peavy, D P Salmon, et al.Biochemical and Biophysical Research Communications|February 19, 2000
Amyloid-beta peptides interact with plasma proteins and erythrocytes: implications for their quantitation in plasmaY M Kuo, T A Kokjohn, W Kalback, et al.Neurology|May 23, 2007
Cycad exposure and risk of dementia, MCI, and PDC in the Chamorro population of GuamA R Borenstein, J A Mortimer, E Schofield, et al.Neurobiology of Aging|January 4, 2011
Amyloid precursor protein (APP) processing genes and cerebrospinal fluid APP cleavage product levels in Alzheimer's diseaseL M Bekris, N M Galloway, S Millard, et al.Proceedings of the National Academy of Sciences of the United States of America|July 8, 2009
Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's diseaseM Britschgi, C E Olin, H T Johns, et al.Pageof 1